Showing 65–77 of 77 items from the last 14 days
Gold prices could surge past Goldman Sachs's $4 900 year-end forecast, as surging demand for bullish gold options may amplify further gains, the bank said in a note on Friday. The bank said a further pickup in Western investor demand, combined with continued strong central bank buying, could push bullion toward key option strike levels, where dealer hedging may mechanically accelerate price moves.
Read original →London-listed Galileo Resources and partner Statunga Investments maintain their 75%/25% joint venture stake in Zambia's Luansobe copper project (licences 34543/HQ/SML and 34545/HQ/SML) and are pursuing ownership disputes through legal channels. Unresolved title disputes delay copper development in a region where supply chain security is increasingly material to EV and renewable energy sectors.
Read original →South Africa's Minerals Council endorsed President Cyril Ramaphosa's launch of the Government-Business Partnership for Growth and Jobs Phase 3, targeting 3% economic growth and one million jobs by 2030. The initiative aims to restore investor confidence and capital inflows to South Africa's mining and resources sector.
Read original →Zinc prices on the London Metal Exchange hit $3,823.85 per metric ton, the highest level in over four years, driven by supply concerns and Chinese demand accumulation. Elevated zinc prices affect manufacturers of alloys, galvanized steel, and electronics, which are inputs for semiconductor equipment and renewable energy infrastructure.
Read original →Goliath Resources' drill hole GD-26-436 at the Surebet discovery in British Columbia's Golden Triangle intersected gold-equivalent grades of 19.51 g/t over 8.32 meters, with the zone remaining open for expansion. High-grade gold discoveries near surface indicate exploration success that could support future production and meet growing gold demand from electronics and renewable energy applications.
Read original →1911 Gold Corporation (“1911 Gold” or the “Company“) (TSXV: AUMB) (OTCBB: AUMBF) (FRA: 2KY) is pleased to...
Read original →Yukon Metals Corp. (CSE: YMC, FSE: E770, OTCQB: YMMCF) (“Yukon Metals” or the “Company“) has...
Read original →An experimental personalized mRNA vaccine developed by Moderna (NASDAQ:MRNA) and Merck & Company (NYSE:MRK) successfully prevented skin cancer from returning in a late-stage clinical trial, sending shares of both drugmakers surging on Wednesday (August 19). The Phase 3 study evaluated the personalized vaccine, named intismeran, in combination with Merck’s immunotherapy drug Keytruda against Keytruda alone in 1,137 high-risk melanoma patients who had undergone surgery to remove their tumors. The combination regimen met its primary endpoint by significantly extending recurrence-free survival and achieved its secondary goal of reducing the risk of cancer metastasizing to distant organs. The findings sparked a massive rally for both companies. Moderna shares surged as much as 177 percent to a two-year high of US$174.93, adding roughly US$30 billion to the company's market capitalization as trading volume topped 15 times its 50-day average. Merck rallied by 12 percent to reach an all-time high of US$153.13. Broader sector sentiment climbed alongside the news, lifting the Nasdaq Biotechnology Index up to 5.2 percent to a record high. Moderna and Merck plan to present detailed data at an upcoming medical meeting and have initiated discussions with regulatory agencies. Moderna President Stephen Hoge said the treatment could reach the market as soon as next year under its existing breakthrough therapy designation. Unlike traditional one-size-fits-all oncology treatments, the therapy creates intismeran–the mRNA cancer vaccine–by surgically removing a piece of a patient's tumor and sequencing its DNA to identify unique cellular mutations. Using mRNA technology, the bespoke vaccine instructs the patient's cells to reproduce copies of those specific mutations, training the immune system to recognize and attack any remaining cancer cells displaying those markers when paired with Keytruda. "This is the first time that we've seen really clinically significant, statistically significant improvements over checkpoints like Keytruda in this population, and it is the first time we've done that with an individualized treatment," Hoge said. The drugmakers are currently running clinical trials testing similar personalized mRNA regimens against lung, kidney, bladder, breast, and pancreatic cancers. As of 10:50 a.m. EST shares of Moderna were priced at US$141.69 and Merck was trading for US$150.51. Don’t forget to follow us @INN_LifeScience for real-time news updates! Securities Disclosure: I, Giann Liguid, hold no direct investment interest in any company mentioned in this article.
Read original →Exxaro wants its growing energy and future-facing metals businesses to account for more than half of group earnings by 2030. “This is the business we are building for tomorrow,” Exxaro CEO Ben Magara said while displaying a slide showing a diversified natural resources champion not only providing earnings and reducing carbon intensity, but also providing the career opportunities of many young and upcoming people "to make sure that we remain a key driver to our country's economy". (Also watch attached Creamer Media video.)
Read original →The four sectors of mining, agriculture, tourism and infrastructure have been selected under Phase 3 of the Government-Business Partnership as the platforms for raising South Africa’s growth to 3% and to create one-million new jobs by 2030. These new focus areas were unveiled jointly in Johannesburg on August 20 by President Cyril Ramaphosa and Discovery CEO Adrian Gore, a key business convenor of the partnership since its launch in 2023.
Read original →Grande Portage Resources Ltd. (TSXV: GPG) (OTCQX: GPTRF) (FSE: GPB) (“Grande Portage” or the “Company”)...
Read original →Ghana's mineworkers union demanded release of $34.55 million in trapped savings frozen since central bank financial sector reforms completed in 2019. The frozen funds illustrate governance risks in mining-dependent economies and potential impact on worker liquidity and regional mining labor stability.
Read original →Troilus Mining Corp. announced new drilling results from its Troilus Project, reinforcing underground mineral potential. Positive exploration results strengthen project development trajectory and capital investment case for gold and base metal extraction.
Read original →
DailySand